Day: March 6, 2025

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $22.8 million, or $.80 per share, in the fourth quarter of 2024 compared to net income of $4.9 million, or $.17 per share, in the fourth quarter of 2023. For the full year of 2024, Valhi reported net income attributable to Valhi stockholders of $108.0 million, or $3.79 per share, compared to a net loss of $9.9 million, or $.35 per share, for the full year of 2023. Net income attributable to Valhi stockholders increased in the fourth quarter of 2024 as compared to the fourth quarter of 2023 primarily due to higher operating results from the Chemicals Segment and aggregate income of $31.4 million ($20.6 million, or $.72 per share, net of tax and noncontrolling interest) related to the settlement of a...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors Significantly expanded equity research coverageSAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. “2024 was a transformational year for Cidara as we reacquired rights to the CD388 program, our long-acting, universal influenza drug, and raised $240.0 million in April to conduct the 5,000 subject Phase 2b NAVIGATE trial evaluating CD388 for...

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) —          NL Industries, Inc. (NYSE: NL) today reported net income attributable to NL stockholders of $16.5 million, or $.34 per share, in the fourth quarter of 2024 compared to net income attributable to NL stockholders of $7.6 million, or $.16 per share, in the fourth quarter of 2023. NL’s results include an unrealized loss of $12.0 million in the fourth quarter of 2024 compared to a $2.4 million unrealized gain in the fourth quarter of 2023 related to the change in value of marketable equity securities. For the full year of 2024, NL reported net income attributable to NL stockholders of $67.2 million, or $1.38 per share, compared to a net loss attributable to NL stockholders of $2.3 million, or $.05 per share for the full year of 2023. NL’s full year results include an unrealized...

VERO BEACH, Fla., March 06, 2025 (GLOBE NEWSWIRE) — Bimini Capital Management, Inc. (OTCQB: BMNM), (“Bimini Capital,” “Bimini,” or the “Company”), today announced results of operations for the three-month period ended December 31, 2024. Fourth Quarter 2024 HighlightsNet loss of $1.5 million, or $0.15 per common share Book value per share of $0.68 Company to discuss results on Friday, March 7, 2025, at 10:00 AM ETManagement Commentary Commenting on the fourth quarter results, Robert E. Cauley, Chairman and Chief Executive Officer, said, “The outlook for the fixed income market pivoted early in the fourth quarter of 2024. As the third quarter came to an end, inflation was falling towards the Fed’s 2% target, the labor market was cooling as hiring levels moderated and the unemployment rate was slowly creeping higher, and the Fed...

– Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways – – FA: FDA Investigational New Drug (IND) clearance for first-in-human clinical study of SGT-212 utilizing a dual route of administration to treat Friedreich’s ataxia (FA); Dosing of first participant anticipated in the second half of 2025 – – CPVT: IND for SGT-501 on track for first half 2025 submission – – Cash: Company ended 2024 with $148.9 million in cash, cash equivalents, investments and available-for-sale securities; Combined with gross proceeds from $200.0 million underwritten offering in February 2025, Solid has anticipated...

Fourth Quarter Sales of $71.4 million, Adjusted EBITDA of $4.4 million, and Free Cash Flow of $14.4 million Completed the Acquisition of RockyMounts, Expanding Adventure’s Bike-Rack Product Capabilities Globally SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year‐Ago Quarter (adjusted to reflect the reclassification of the Precision Sport segment as discontinued operations)Sales of $71.4 million compared to $76.5 million. Gross margin was 33.4% compared to 28.9%; adjusted gross margin of 38.0% compared to 34.7%. Net loss, which includes the impact of discontinued operations,...

SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025.Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million. GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year’s first quarter. Non-GAAP diluted EPS of $0.92, up $0.07 from last year’s first quarter. See “Reconciliation of Selected GAAP Results to Non-GAAP Results” below.Commenting on the results, Al White, Cooper’s President and CEO said, “We started the year on a positive note meeting our revenue expectations and exceeding our operational targets. Moving forward,...

Dallas, Texas, March 06, 2025 (GLOBE NEWSWIRE) — Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $13.2 million, or $.12 per share, in the fourth quarter of 2024 compared to a net loss of $5.3 million, or $.05 per share, in the fourth quarter of 2023. For the full year of 2024, Kronos Worldwide reported net income of $86.2 million, or $.75 per share, compared to a net loss of $49.1 million, or $.43 per share, for the full year of 2023. Net income decreased in the fourth quarter 2024 compared to the fourth quarter of 2023 primarily due to increases in the Company’s income tax expense resulting from (i) final tax regulations on the treatment of certain currency translation gains and losses, which resulted in a non-cash deferred income tax expense of $16.5 million ($.14 per share) and (ii) the recognition of a deferred...

VIRGINIA CITY, Nev., March 06, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2024 results, 2024 summary achievements, and our 2025 business outlook. “As of today, we achieved all of our previously published 2024 objectives for both our metals and fuels segments, including fully commissioning, operating and establishing market leadership in photovoltaic recycling, that is now rapidly growing and expanding into full industry-scale, and fuels, who has executed multiple, future revenue generating commercial agreements for industry-scale development projects, including offtakes, supply of feedstocks and joint development agreements with operationally experienced, technologically sophisticated and well capitalized customers and partners,” stated Corrado De Gasperis,...